RxDoctor Payments Data

Barry Pronold, MD

Gastroenterology · Troy, NYNPI 1144420837

Payments from drug & device makers

$3,591in general payments, 2019–2025

Across 77 payments — averaging $46.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Redhill Biopharma Inc.$2K
  • AbbVie$890
  • Johnson & Johnson$310
  • Phathom Pharmaceuticals, Inc.$150
  • Intercept Pharmaceuticals, Inc.$129
  • Mallinckrodt Hospital Products Inc.$129
  • plus $484 from 10 others

What the payments were for

  • Speaking & faculty fees$1,50042%
  • Food & beverage$2,09158%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,591 in reported general payments places this provider in the 60th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$105,926
Medicare patients
445
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab15$224,596
CreonLipase/Protease/Amylase18$62,467
XifaxanRifaximin13$34,967
LinzessLinaclotide25$24,152
Mesalamine33$13,186
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates86$5,698
Ursodiol16$5,538
Omeprazole364$4,513
Colesevelam Hcl27$2,341
Pantoprazole Sodium155$1,875
Mesalamine DrMesalamine11$1,420
Famotidine76$1,304
Lactulose14$705
Lansoprazole28$550
Sucralfate13$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$890$86,62043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Troy

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →